Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Start For LG’s Biosimilar Humira In Crowded Korean Sector

This article was originally published in PharmAsia News

Executive Summary

Competition is becoming ever fiercer in the South Korean biosimilars sector as LG Life Sciences begins late stage clinical development for another project, moving it a step closer to commercialization. Its biosimilar versions of Humira and Enbrel have also entered Phase III trials in Japan with local partner Mochida.

You may also be interested in...



Voronoi’s Brain-Permeable NSCLC Candidate Attracts ORIC To Major Deal

Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Helixmith Plunges On Warning Of Possible Offering Delay

Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel